Liver/Biliary Disorders News

To streamline and validate diagnosis of and clinical trials in non-alcoholic steatohepatitis, one group is on a mission to determine the best non-invasive tests for all physicians to use, according to a presentation.

Vonafexor induced a strong reduction in liver fat content and improvements in biochemical and imaging markers of liver inflammation and kidney function, according to a presenter at The Liver Meeting Digital Experience.

A 6-month Lactobacillus rhamnosus GG treatment for moderate alcohol-associated hepatitis correlated with a decrease in heavy drinking levels to the social drinking or abstinence levels, according to a presentation.

Aldafermin did not reach statistical significance on dose-dependent improvement in fibrosis on liver biopsy in patients with nonalcoholic steatohepatitis, according to a presentation at The Liver Meeting Digital Experience.

Adding normothermic machine perfusion to an existing liver transplant program would add quality adjusted life years while saving money and proving cost effective, according to a presentation at The Liver Meeting Digital Experience.

Consultations, testing and treatment of hepatitis B and C virus fell significantly during the first year of the COVID-19 pandemic, with many centers seeing declines of more than 75% in all categories, according to a presentation.

According to a presenter at The Liver Meeting Digital Experience, diagnosis and treatment for hepatitis B virus remains low; therefore, significant increases in treatment are needed to decrease disease burden.

Compared to current practices of annual screening for hepatitis C virus in men who have sex with men, working toward reducing their risk and screening every 6 months could prove cost effective, according to a presentation.

COVID-19 vaccination correlated with a decreased risk for hospitalization among patients with cirrhosis and other high-risk comorbidities, according to research presented at The Liver Meeting Digital Experience.

Protection provided by the mRNA COVID vaccinations is slower to build to efficacy and lower overall in patients with cirrhosis as compared to unvaccinated controls, according to a presentation at The Liver Meeting Digital Experience.